Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer
Abstract
Resistance to endocrine therapy in estrogen receptor–positive (ER+) breast cancer remains a significant clinical problem. Riluzole is FDA-approved for the treatment of amyotrophic lateral sclerosis. A benzothiazole-based glutamate release inhibitor with several context-dependent mechanism(s) of action, riluzole has shown antitumor activity in multiple malignancies, including melanoma, glioblastoma, and breast cancer. We previously reported that the acquisition of tamoxifen resistance in a cellular model of invasive lobular breast cancer is accompanied by the upregulation of GRM mRNA expression and growth inhibition by riluzole.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 28, 2023
- Source ID
- 10.1210/jendso/bvad117
Entities
People
- Aaron M Rozeboom
- Ayodeji O Olukoya
- Britta Jacobsen
- Carlos Benitez
- Deborah L. Berry
- Ganesh V Raj
- Hannah Ceuleers
- Hillary Stires
- M Idalia Cruz
- Rebecca B Riggins
- Shaymaa Bahnassy
- Shihong Ma
- Sonali Persaud
- Suman Ranjit
- Yanira Guerra
Organizations
- Georgetown University
- National Cancer Institute
- National Institutes of Health
- United States Department of Defense
- University of Colorado
- University of Texas at Austin